• DNDi logo
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Dengue
      • COVID-19
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • HAT Platform
      • HELP Helminth Elimination Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Global Headquarters
      • DNDi DRC
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia/India
      • DNDi South-East Asia
      • DNDi Southern Africa
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
DNDi logo
  • DNDi logo
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Dengue
      • COVID-19
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • HAT Platform
      • HELP Helminth Elimination Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Global Headquarters
      • DNDi DRC
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia/India
      • DNDi South-East Asia
      • DNDi Southern Africa
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
Home > Press releases

Patient access to miltefosine in developing countries not secure despite award of US FDA PRV sold for USD 125 million

Geneva, Switzerland / New York, USA — 25 Nov 2014
Share on twitter
Share on facebook
Share on linkedin
Share on email
Share on print

DNDi and MSF urge Knight Therapeutics, Paladin, and Endo to commit to key drug access requirements for treatment of leishmaniasis worldwide
Knight Therapeutics has landed a USD 125 million windfall after selling its Priority Review Voucher (PRV) granted for the registration of miltefosine (Impavido®), even while access to the life-saving drug remains unsecured. The Drugs for Neglected Diseases initiative (DNDi) and Médécins Sans Frontières Access Campaign (MSF) are urging the drug’s license-holders and manufacturers – Knight Therapeutics, Paladin, and Endo – to ensure broad, sustainable access to the drug for the millions of people who need it.

In March 2014, Knight Therapeutics was awarded a Priority Review Voucher by the US Food and Drug Administration (FDA) for registering miltefosine in the United States. The FDA PRV is an incentive that aims at rewarding research and development (R&D) for new treatments for neglected tropical diseases. However, the R&D for miltefosine use in treating leishmaniasis was largely conducted in the mid-1990s by the WHO/TDR (Special Programme for Research and Training in Tropical Diseases) and partners, with private and public funding. Since then, DNDi and partners have invested in clinical studies testing the drug. Neither Paladin/Endo, nor Knight Therapeutics, has invested significantly in the R&D for the drug, but Knight Therapeutics will now benefit to the tune of USD 125 million after selling its Priority Review Voucher to Gilead.

Miltefosine is a vital drug in the currently fragile treatment arsenal for both visceral and cutaneous forms of leishmaniasis, a disease with over 1.3 million new cases and up to 40,000 deaths each year from the visceral form. There are currently only four drugs included in the World Health Organization’s Essential Medicines List for the treatment of leishmaniasis globally, including miltefosine.

Knight Therapeutics holds the exclusive license to distribute miltefosine (Impavido®) for leishmaniasis in the USA, whereas Paladin/Endo have maintained exclusive distribution and manufacturing rights for the rest of the world. Access to miltefosine in low- and middle-income countries with the highest disease burden has been inconsistent over recent years, with drug shortages, large minimum purchase requirements by the manufacturers, and a lack of response to public tenders where the drug was much needed, including in endemic countries such as India. In addition to its current use in Asia, the drug is being tested by DNDi and partners in Latin America and in Africa.

DNDi and MSF urge Knight Therapeutics, Paladin, and Endo to respond to the health needs of patients suffering from this neglected disease and to commit immediately to the following:

  • Disclose the actual cost of production of the drug;
  • Price the drug at-cost or with a minimal profit margin to ensure sustainable production of the drug (regardless of ordered quantities);
  • Maintain the registration of the drug in all disease-endemic countries for both visceral leishmaniasis and cutaneous leishmaniasis; and
  • Support additional clinical studies to optimize the use of miltefosine, including pharmacovigilance, dosing in children, use in cutaneous leishmaniasis and other complicated dermal forms of the disease, as well as co-infection with HIV.

The blatant hindrances to patient access to miltefosine for this neglected disease should be examined to the same extent as, and in conjunction with, the important economic benefit that Knight Therapeutics has received for selling the PRV for R&D that the company did not carry out. The PRV mechanism, which aims to stimulate or at least reward drug development for neglected diseases, currently contains no access provisions and fails to ensure that only entities that invested in R&D are awarded the voucher. MSF, DNDi, and others outlined their concerns about the US FDA PRV mechanism in a letter to the US Congress in July this year and have called for improvements to its design and implementation. With the PRV mechanism currently being amended by Congress to extend its applicability to Ebola, the opportunity to improve this important incentive mechanism should not be missed.

For more information on the FDA PRV for milestone: BMJ 2014;349:g4665 – US incentive scheme for neglected diseases: a good idea gone wrong? http://www.bmj.com/content/349/bmj.g4665

Letter sent to US Congress available upon request.

Media contacts:
MSF Access Campaign, Joanna Keenan, +41 79 203 13 02; joanna.keenan@geneva.msf.org
DNDi, Violaine Dallenbach (Europe) +41 79 424 14 74; vdallenbach@dndi.org
DNDi, Ilan Moss (USA) +1-646-266-5216; imoss@dndi.org

Funding Registration & access Visceral leishmaniasis

Read, watch, share

Loading...
Doctor with patient in hospital setting
News
15 Aug 2022

DNDi Media Workshop 2022 for Asian Science and Health Journalists

Viewpoints
12 Aug 2022

The climate crisis and infectious diseases: what role for DNDi?

Laboratory assistant conducts analysis at laboratory in Peru
Press releases
3 Aug 2022

Network of experts calls for urgent boost to research and development of rapid tests for cutaneous leishmaniasis in Latin America

From neglect to hope: Voices of leishmaniasis film poster
Videos
2 Aug 2022

From neglect to hope: Voices of leishmaniasis

Mother with her two children, Indian woman, and African doctor
Publications
1 Aug 2022

New hope for leishmaniasis

Lab activities
Press releases
27 Jul 2022

Korean cutting-edge technology to reduce the cost of promising drug for neglected disease visceral leishmaniasis

Statements
18 Jul 2022

DNDi‘s comments on the working draft of the WHO CAll for the consideration of the INB at its second meeting

Man standing by the river
Publications
15 Jul 2022

DNDi 2021 Annual Report

VIEW ALL

Help neglected patients

To date, we have delivered twelve new treatments, saving millions of lives.

Our goal is to deliver 25 new treatments in our first 25 years. You can help us get there. 

GIVE NOW
DNDi logo
Facebook-f
Twitter
Instagram
Linkedin-in
Youtube
International non-profit developing safe, effective, and affordable treatments for the most neglected patients.

Learn more

  • Diseases
  • R&D portfolio
  • Policy advocacy

Get in touch

  • Our offices
  • Contact us
  • Integrity Line

Support us

  • Donate
  • Subscribe to eNews

Work with us

  • Join research networks
  • Jobs
  • RFPs
  • Terms of Use   
  •   Acceptable Use Policy   
  •   Privacy Policy   
  •   Cookie Policy   
  •   Our policies   

  • Except for images, films and trademarks which are subject to DNDi’s Terms of Use, content on this site is licensed under a Creative Commons Attribution-NonCommercial-Share Alike 3.0 Switzerland License   
We use cookies to track our audience and improve our content. By clicking 'Accept All', you are agreeing to our use of cookies. Click on 'Customize' to accept only some cookies.
Customize
ACCEPT ALL
Manage consent

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
CookieDurationDescription
cookielawinfo-checkbox-advertisement1 yearSet by the GDPR Cookie Consent plugin, this cookie is used to record the user consent for the cookies in the "Advertisement" category .
cookielawinfo-checkbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
CookieLawInfoConsent1 yearRecords the default button state of the corresponding category & the status of CCPA. It works only in coordination with the primary cookie.
elementorneverThis cookie is used by the website's WordPress theme. It allows the website owner to implement or change the website's content in real-time.
PHPSESSIDsessionThis cookie is native to PHP applications. The cookie is used to store and identify a users' unique session ID for the purpose of managing user session on the website. The cookie is a session cookies and is deleted when all the browser windows are closed.
viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
Functional
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
Analytics
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
CookieDurationDescription
_ga2 yearsThe _ga cookie, installed by Google Analytics, calculates visitor, session and campaign data and also keeps track of site usage for the site's analytics report. The cookie stores information anonymously and assigns a randomly generated number to recognize unique visitors.
_ga_16Q5RH3XRG2 yearsThis cookie is installed by Google Analytics.
_gat_UA-10302561-11 minuteA variation of the _gat cookie set by Google Analytics and Google Tag Manager to allow website owners to track visitor behaviour and measure site performance. The pattern element in the name contains the unique identity number of the account or website it relates to.
_gid1 dayInstalled by Google Analytics, _gid cookie stores information on how visitors use a website, while also creating an analytics report of the website's performance. Some of the data that are collected include the number of visitors, their source, and the pages they visit anonymously.
_hjAbsoluteSessionInProgress30 minutesHotjar sets this cookie to detect the first pageview session of a user. This is a True/False flag set by the cookie.
_hjFirstSeen30 minutesHotjar sets this cookie to identify a new user’s first session. It stores a true/false value, indicating whether it was the first time Hotjar saw this user.
_hjIncludedInPageviewSample2 minutesHotjar sets this cookie to know whether a user is included in the data sampling defined by the site's pageview limit.
_hjIncludedInSessionSample2 minutesHotjar sets this cookie to know whether a user is included in the data sampling defined by the site's daily session limit.
_hjSession_112884430 minutesNo description
CONSENT2 yearsYouTube sets this cookie via embedded youtube-videos and registers anonymous statistical data.
Targeting
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
Others
Other uncategorized cookies are those that are being analyzed and have not been classified into a category as yet.
CookieDurationDescription
_hjSessionUser_11288441 yearNo description
Advertisement
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
SAVE & ACCEPT
Powered by CookieYes Logo